The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery
The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery (TheRAPy): a Multiple Period Vanguard Cluster Crossover Trial
Population Health Research Institute
4,500 participants
Dec 4, 2024
INTERVENTIONAL
Conditions
Summary
The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.
Eligibility
Inclusion Criteria2
- Hospitals completing >200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial.
- All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection.
Exclusion Criteria2
- Complete <=200 cardiac surgical cases.
- <95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery
sites implement crystalloid priming use during cardiac surgery
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06230198